Global Hepatocellular Carcinoma Treatment Drug Market Research Report 2026

Hepatocellular Carcinoma Treatment Drug Market

Hepatocellular carcinoma (HCC) treatment drugs refer to various systemic therapeutic agents used to inhibit tumor growth, prolong patient survival, or improve quality of life. These drugs exert their anti-tumor effects by blocking tumor angiogenesis, regulating signaling pathways, or activating the body's immune system. They are suitable for patients with unresectable or advanced HCC and have become the core means of current systemic treatment for liver cancer. The upstream of the HCC treatment drug industry chain mainly includes raw material (API) suppliers, key intermediate synthesis companies, biological reagent and cell culture consumable manufacturers, and R&D and manufacturing outsourcing organizations that provide CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) services. The midstream consists of innovative pharmaceutical companies and biotechnology companies responsible for target discovery, preclinical research, clinical trials, and drug registration. Representative companies include Roche, Merck, BeiGene, and Hengrui Medicine. The downstream covers hospitals, oncology centers, DTP pharmacies, and medical insurance/commercial insurance payment systems, and achieves commercialization through academic promotion, access negotiations, and patient assistance programs. Since these drugs are mostly high-barrier patented innovative drugs or biologics, they have strong pricing power. The gross profit margin of major global products is generally as high as 80%-90%. Even under the pressure of centralized procurement or medical insurance negotiations, the gross profit margin of core HCC drugs of leading domestic companies can still be maintained at more than 75%, which is significantly higher than that of ordinary generic drugs.

The hepatocellular carcinoma treatment drug market is supported by rising global liver cancer incidence, aging populations, and improved diagnostic capabilities. Targeted therapies and immuno-oncology drugs are increasingly replacing conventional chemotherapy due to superior efficacy and better patient tolerance. Combination therapy strategies are becoming mainstream, driving higher treatment value per patient. Strong pricing power and high gross margins reflect significant R&D investment and regulatory barriers. Emerging markets contribute incremental volume growth as access to oncology care improves. Overall, the market is expected to maintain stable expansion, driven by innovation, clinical guideline updates, and expanding reimbursement coverage.

This report delivers a comprehensive overview of the global Hepatocellular Carcinoma Treatment Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hepatocellular Carcinoma Treatment Drug. The Hepatocellular Carcinoma Treatment Drug market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Hepatocellular Carcinoma Treatment Drug market comprehensively. Regional market sizes by Type, by Application, by Treatment Line, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Hepatocellular Carcinoma Treatment Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Hepatocellular Carcinoma Treatment Drug Market Report

Chapter Outline

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Targeted Therapy Drugs

1.2.3 Immune Checkpoint Inhibitors

1.2.4 Chemotherapy Drugs

1.3 Market by Treatment Line

1.3.1 Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Treatment Line: 2021 vs 2025 vs 2032

1.3.2 First-line HCC Therapy

1.3.3 Second-line HCC Therapy

1.3.4 Adjuvant Therapy

1.3.5 Palliative Drug Treatment

1.4 Market by Administration Route

1.4.1 Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Administration Route: 2021 vs 2025 vs 2032

1.4.2 Oral HCC Drugs

1.4.3 Intravenous Infusion Drugs

1.4.4 Intra-arterial Chemotherapy Drugs

1.5 Market by Application

1.5.1 Global Hepatocellular Carcinoma Treatment Drug Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Below 29 Years

1.5.3 30-49 Years

1.5.4 Above 50 Years

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2.1 Global Hepatocellular Carcinoma Treatment Drug Market Perspective (2021–2032)

2.2 Global Hepatocellular Carcinoma Treatment Drug Growth Trends by Region

2.2.1 Global Hepatocellular Carcinoma Treatment Drug Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Hepatocellular Carcinoma Treatment Drug Historic Market Size by Region (2021–2026)

2.2.3 Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Region (2027–2032)

2.3 Hepatocellular Carcinoma Treatment Drug Market Dynamics

2.3.1 Hepatocellular Carcinoma Treatment Drug Industry Trends

2.3.2 Hepatocellular Carcinoma Treatment Drug Market Drivers

2.3.3 Hepatocellular Carcinoma Treatment Drug Market Challenges

2.3.4 Hepatocellular Carcinoma Treatment Drug Market Restraints

3.1 Global Top Hepatocellular Carcinoma Treatment Drug Players by Revenue

3.1.1 Global Top Hepatocellular Carcinoma Treatment Drug Players by Revenue (2021–2026)

3.1.2 Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Players (2021–2026)

3.2 Global Top Hepatocellular Carcinoma Treatment Drug Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Hepatocellular Carcinoma Treatment Drug Revenue

3.4 Global Hepatocellular Carcinoma Treatment Drug Market Concentration Ratio

3.4.1 Global Hepatocellular Carcinoma Treatment Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Treatment Drug Revenue in 2025

3.5 Global Key Players of Hepatocellular Carcinoma Treatment Drug Head Offices and Areas Served

3.6 Global Key Players of Hepatocellular Carcinoma Treatment Drug, Products and Applications

3.7 Global Key Players of Hepatocellular Carcinoma Treatment Drug, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4.1 Global Hepatocellular Carcinoma Treatment Drug Historic Market Size by Type (2021–2026)

4.2 Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Type (2027–2032)

5.1 Global Hepatocellular Carcinoma Treatment Drug Historic Market Size by Application (2021–2026)

5.2 Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Application (2027–2032)

6.1 North America Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)

6.2 North America Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Hepatocellular Carcinoma Treatment Drug Market Size by Country (2021–2026)

6.4 North America Hepatocellular Carcinoma Treatment Drug Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7.1 Europe Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)

7.2 Europe Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Hepatocellular Carcinoma Treatment Drug Market Size by Country (2021–2026)

7.4 Europe Hepatocellular Carcinoma Treatment Drug Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8.1 Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)

8.2 Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size by Region (2021–2026)

8.4 Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9.1 Latin America Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)

9.2 Latin America Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Hepatocellular Carcinoma Treatment Drug Market Size by Country (2021–2026)

9.4 Latin America Hepatocellular Carcinoma Treatment Drug Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size (2021–2032)

10.2 Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size by Country (2021–2026)

10.4 Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11.1 Merck & Co.

11.1.1 Merck & Co. Company Details

11.1.2 Merck & Co. Business Overview

11.1.3 Merck & Co. Hepatocellular Carcinoma Treatment Drug Introduction

11.1.4 Merck & Co. Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.1.5 Merck & Co. Recent Development

11.2 Bayer

11.2.1 Bayer Company Details

11.2.2 Bayer Business Overview

11.2.3 Bayer Hepatocellular Carcinoma Treatment Drug Introduction

11.2.4 Bayer Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.2.5 Bayer Recent Development

11.3 Roche

11.3.1 Roche Company Details

11.3.2 Roche Business Overview

11.3.3 Roche Hepatocellular Carcinoma Treatment Drug Introduction

11.3.4 Roche Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.3.5 Roche Recent Development

11.4 Eli Lilly and Company

11.4.1 Eli Lilly and Company Company Details

11.4.2 Eli Lilly and Company Business Overview

11.4.3 Eli Lilly and Company Hepatocellular Carcinoma Treatment Drug Introduction

11.4.4 Eli Lilly and Company Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.4.5 Eli Lilly and Company Recent Development

11.5 Bristol-Myers Squibb

11.5.1 Bristol-Myers Squibb Company Details

11.5.2 Bristol-Myers Squibb Business Overview

11.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Treatment Drug Introduction

11.5.4 Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.5.5 Bristol-Myers Squibb Recent Development

11.6 Exelixis Inc

11.6.1 Exelixis Inc Company Details

11.6.2 Exelixis Inc Business Overview

11.6.3 Exelixis Inc Hepatocellular Carcinoma Treatment Drug Introduction

11.6.4 Exelixis Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.6.5 Exelixis Inc Recent Development

11.7 Innovent Biologics Inc

11.7.1 Innovent Biologics Inc Company Details

11.7.2 Innovent Biologics Inc Business Overview

11.7.3 Innovent Biologics Inc Hepatocellular Carcinoma Treatment Drug Introduction

11.7.4 Innovent Biologics Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.7.5 Innovent Biologics Inc Recent Development

11.8 Akeso, Inc

11.8.1 Akeso, Inc Company Details

11.8.2 Akeso, Inc Business Overview

11.8.3 Akeso, Inc Hepatocellular Carcinoma Treatment Drug Introduction

11.8.4 Akeso, Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.8.5 Akeso, Inc Recent Development

11.9 Jiangsu Hengrui Medicine Co Ltd

11.9.1 Jiangsu Hengrui Medicine Co Ltd Company Details

11.9.2 Jiangsu Hengrui Medicine Co Ltd Business Overview

11.9.3 Jiangsu Hengrui Medicine Co Ltd Hepatocellular Carcinoma Treatment Drug Introduction

11.9.4 Jiangsu Hengrui Medicine Co Ltd Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.9.5 Jiangsu Hengrui Medicine Co Ltd Recent Development

11.10 AstraZeneca Plc

11.10.1 AstraZeneca Plc Company Details

11.10.2 AstraZeneca Plc Business Overview

11.10.3 AstraZeneca Plc Hepatocellular Carcinoma Treatment Drug Introduction

11.10.4 AstraZeneca Plc Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.10.5 AstraZeneca Plc Recent Development

11.11 BeiGene

11.11.1 BeiGene Company Details

11.11.2 BeiGene Business Overview

11.11.3 BeiGene Hepatocellular Carcinoma Treatment Drug Introduction

11.11.4 BeiGene Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.11.5 BeiGene Recent Development

11.12 Sanofi SA

11.12.1 Sanofi SA Company Details

11.12.2 Sanofi SA Business Overview

11.12.3 Sanofi SA Hepatocellular Carcinoma Treatment Drug Introduction

11.12.4 Sanofi SA Revenue in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

11.12.5 Sanofi SA Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

 Table 1. Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

 Table 2. Key Players of Targeted Therapy Drugs

 Table 3. Key Players of Immune Checkpoint Inhibitors

 Table 4. Key Players of Chemotherapy Drugs

 Table 5. Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Treatment Line (US$ Million): 2021 vs 2025 vs 2032

 Table 6. Key Players of First-line HCC Therapy

 Table 7. Key Players of Second-line HCC Therapy

 Table 8. Key Players of Adjuvant Therapy

 Table 9. Key Players of Palliative Drug Treatment

 Table 10. Global Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Administration Route (US$ Million): 2021 vs 2025 vs 2032

 Table 11. Key Players of Oral HCC Drugs

 Table 12. Key Players of Intravenous Infusion Drugs

 Table 13. Key Players of Intra-arterial Chemotherapy Drugs

 Table 14. Global Hepatocellular Carcinoma Treatment Drug Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

 Table 15. Global Hepatocellular Carcinoma Treatment Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 16. Global Hepatocellular Carcinoma Treatment Drug Market Size by Region (US$ Million), 2021–2026

 Table 17. Global Hepatocellular Carcinoma Treatment Drug Market Share by Region (2021–2026)

 Table 18. Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Region (US$ Million), 2027–2032

 Table 19. Global Hepatocellular Carcinoma Treatment Drug Market Share by Region (2027–2032)

 Table 20. Hepatocellular Carcinoma Treatment Drug Market Trends

 Table 21. Hepatocellular Carcinoma Treatment Drug Market Drivers

 Table 22. Hepatocellular Carcinoma Treatment Drug Market Challenges

 Table 23. Hepatocellular Carcinoma Treatment Drug Market Restraints

 Table 24. Global Hepatocellular Carcinoma Treatment Drug Revenue by Players (US$ Million), 2021–2026

 Table 25. Global Hepatocellular Carcinoma Treatment Drug Market Share by Players (2021–2026)

 Table 26. Global Top Hepatocellular Carcinoma Treatment Drug Players by Tier (Tier 1, Tier 2, and Tier 3), based on Hepatocellular Carcinoma Treatment Drug Revenue, 2025

 Table 27. Ranking of Global Top Hepatocellular Carcinoma Treatment Drug Companies by Revenue (US$ Million) in 2025

 Table 28. Global 5 Largest Players Market Share by Hepatocellular Carcinoma Treatment Drug Revenue (CR5 and HHI), 2021–2026

 Table 29. Global Key Players of Hepatocellular Carcinoma Treatment Drug, Headquarters and Area Served

 Table 30. Global Key Players of Hepatocellular Carcinoma Treatment Drug, Products and Applications

 Table 31. Global Key Players of Hepatocellular Carcinoma Treatment Drug, Date of General Availability (GA)

 Table 32. Mergers and Acquisitions, Expansion Plans

 Table 33. Global Hepatocellular Carcinoma Treatment Drug Market Size by Type (US$ Million), 2021–2026

 Table 34. Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Type (2021–2026)

 Table 35. Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Type (US$ Million), 2027–2032

 Table 36. Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Type (2027–2032)

 Table 37. Global Hepatocellular Carcinoma Treatment Drug Market Size by Application (US$ Million), 2021–2026

 Table 38. Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Application (2021–2026)

 Table 39. Global Hepatocellular Carcinoma Treatment Drug Forecasted Market Size by Application (US$ Million), 2027–2032

 Table 40. Global Hepatocellular Carcinoma Treatment Drug Revenue Market Share by Application (2027–2032)

 Table 41. North America Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 42. North America Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2021–2026

 Table 43. North America Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2027–2032

 Table 44. Europe Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 45. Europe Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2021–2026

 Table 46. Europe Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2027–2032

 Table 47. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 48. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size by Region (US$ Million), 2021–2026

 Table 49. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size by Region (US$ Million), 2027–2032

 Table 50. Latin America Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 51. Latin America Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2021–2026

 Table 52. Latin America Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2027–2032

 Table 53. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

 Table 54. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2021–2026

 Table 55. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size by Country (US$ Million), 2027–2032

 Table 56. Merck & Co. Company Details

 Table 57. Merck & Co. Business Overview

 Table 58. Merck & Co. Hepatocellular Carcinoma Treatment Drug Product

 Table 59. Merck & Co. Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 60. Merck & Co. Recent Development

 Table 61. Bayer Company Details

 Table 62. Bayer Business Overview

 Table 63. Bayer Hepatocellular Carcinoma Treatment Drug Product

 Table 64. Bayer Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 65. Bayer Recent Development

 Table 66. Roche Company Details

 Table 67. Roche Business Overview

 Table 68. Roche Hepatocellular Carcinoma Treatment Drug Product

 Table 69. Roche Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 70. Roche Recent Development

 Table 71. Eli Lilly and Company Company Details

 Table 72. Eli Lilly and Company Business Overview

 Table 73. Eli Lilly and Company Hepatocellular Carcinoma Treatment Drug Product

 Table 74. Eli Lilly and Company Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 75. Eli Lilly and Company Recent Development

 Table 76. Bristol-Myers Squibb Company Details

 Table 77. Bristol-Myers Squibb Business Overview

 Table 78. Bristol-Myers Squibb Hepatocellular Carcinoma Treatment Drug Product

 Table 79. Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 80. Bristol-Myers Squibb Recent Development

 Table 81. Exelixis Inc Company Details

 Table 82. Exelixis Inc Business Overview

 Table 83. Exelixis Inc Hepatocellular Carcinoma Treatment Drug Product

 Table 84. Exelixis Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 85. Exelixis Inc Recent Development

 Table 86. Innovent Biologics Inc Company Details

 Table 87. Innovent Biologics Inc Business Overview

 Table 88. Innovent Biologics Inc Hepatocellular Carcinoma Treatment Drug Product

 Table 89. Innovent Biologics Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 90. Innovent Biologics Inc Recent Development

 Table 91. Akeso, Inc Company Details

 Table 92. Akeso, Inc Business Overview

 Table 93. Akeso, Inc Hepatocellular Carcinoma Treatment Drug Product

 Table 94. Akeso, Inc Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 95. Akeso, Inc Recent Development

 Table 96. Jiangsu Hengrui Medicine Co Ltd Company Details

 Table 97. Jiangsu Hengrui Medicine Co Ltd Business Overview

 Table 98. Jiangsu Hengrui Medicine Co Ltd Hepatocellular Carcinoma Treatment Drug Product

 Table 99. Jiangsu Hengrui Medicine Co Ltd Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 100. Jiangsu Hengrui Medicine Co Ltd Recent Development

 Table 101. AstraZeneca Plc Company Details

 Table 102. AstraZeneca Plc Business Overview

 Table 103. AstraZeneca Plc Hepatocellular Carcinoma Treatment Drug Product

 Table 104. AstraZeneca Plc Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 105. AstraZeneca Plc Recent Development

 Table 106. BeiGene Company Details

 Table 107. BeiGene Business Overview

 Table 108. BeiGene Hepatocellular Carcinoma Treatment Drug Product

 Table 109. BeiGene Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 110. BeiGene Recent Development

 Table 111. Sanofi SA Company Details

 Table 112. Sanofi SA Business Overview

 Table 113. Sanofi SA Hepatocellular Carcinoma Treatment Drug Product

 Table 114. Sanofi SA Revenue in Hepatocellular Carcinoma Treatment Drug Business (US$ Million), 2021–2026

 Table 115. Sanofi SA Recent Development

 Table 116. Research Programs/Design for This Report

 Table 117. Key Data Information from Secondary Sources

 Table 118. Key Data Information from Primary Sources

 Table 119. Authors List of This Report

List of Figures

 Figure 1. Hepatocellular Carcinoma Treatment Drug Picture

 Figure 2. Global Hepatocellular Carcinoma Treatment Drug Market Size Comparison by Type (US$ Million), 2021–2032

 Figure 3. Global Hepatocellular Carcinoma Treatment Drug Market Share by Type: 2025 vs 2032

 Figure 4. Targeted Therapy Drugs Features

 Figure 5. Immune Checkpoint Inhibitors Features

 Figure 6. Chemotherapy Drugs Features

 Figure 7. Global Hepatocellular Carcinoma Treatment Drug Market Size Comparison by Treatment Line (US$ Million), 2021–2032

 Figure 8. First-line HCC Therapy Features

 Figure 9. Second-line HCC Therapy Features

 Figure 10. Adjuvant Therapy Features

 Figure 11. Palliative Drug Treatment Features

 Figure 12. Global Hepatocellular Carcinoma Treatment Drug Market Size Comparison by Administration Route (US$ Million), 2021–2032

 Figure 13. Oral HCC Drugs Features

 Figure 14. Intravenous Infusion Drugs Features

 Figure 15. Intra-arterial Chemotherapy Drugs Features

 Figure 16. Global Hepatocellular Carcinoma Treatment Drug Market Size by Application (US$ Million), 2021–2032

 Figure 17. Global Hepatocellular Carcinoma Treatment Drug Market Share by Application: 2025 vs 2032

 Figure 18. Below 29 Years Case Studies

 Figure 19. 30-49 Years Case Studies

 Figure 20. Above 50 Years Case Studies

 Figure 21. Hepatocellular Carcinoma Treatment Drug Report Years Considered

 Figure 22. Global Hepatocellular Carcinoma Treatment Drug Market Size (US$ Million), Year-over-Year: 2021–2032

 Figure 23. Global Hepatocellular Carcinoma Treatment Drug Market Size, (US$ Million), 2021 vs 2025 vs 2032

 Figure 24. Global Hepatocellular Carcinoma Treatment Drug Market Share by Region: 2025 vs 2032

 Figure 25. Global Hepatocellular Carcinoma Treatment Drug Market Share by Players in 2025

 Figure 26. Global Hepatocellular Carcinoma Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

 Figure 27. The Top 10 and 5 Players Market Share by Hepatocellular Carcinoma Treatment Drug Revenue in 2025

 Figure 28. North America Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 29. North America Hepatocellular Carcinoma Treatment Drug Market Share by Country (2021–2032)

 Figure 30. United States Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 31. Canada Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 32. Europe Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 33. Europe Hepatocellular Carcinoma Treatment Drug Market Share by Country (2021–2032)

 Figure 34. Germany Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 35. France Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 36. U.K. Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 37. Italy Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 38. Russia Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 39. Ireland Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 40. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 41. Asia-Pacific Hepatocellular Carcinoma Treatment Drug Market Share by Region (2021–2032)

 Figure 42. China Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 43. Japan Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 44. South Korea Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 45. Southeast Asia Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 46. India Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 47. Australia & New Zealand Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 48. Latin America Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 49. Latin America Hepatocellular Carcinoma Treatment Drug Market Share by Country (2021–2032)

 Figure 50. Mexico Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 51. Brazil Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 52. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 53. Middle East & Africa Hepatocellular Carcinoma Treatment Drug Market Share by Country (2021–2032)

 Figure 54. Israel Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 55. Saudi Arabia Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 56. UAE Hepatocellular Carcinoma Treatment Drug Market Size YoY Growth (US$ Million), 2021–2032

 Figure 57. Merck & Co. Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 58. Bayer Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 59. Roche Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 60. Eli Lilly and Company Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 62. Exelixis Inc Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 63. Innovent Biologics Inc Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 64. Akeso, Inc Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 65. Jiangsu Hengrui Medicine Co Ltd Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 66. AstraZeneca Plc Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 67. BeiGene Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 68. Sanofi SA Revenue Growth Rate in Hepatocellular Carcinoma Treatment Drug Business (2021–2026)

 Figure 69. Bottom-up and Top-down Approaches for This Report

 Figure 70. Data Triangulation

 Figure 71. Key Executives Interviewed